gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FHTXHealthcarePharmaceuticals

Foghorn Therapeutics Inc. Common Stock (FHTX)

$2.10−1.41%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.10▼ 40.51% in range
Nov 4, 2025Low $1.85 · High $7.07Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Foghorn Therapeutics closed at $2.10 on Nov 4, down 1.41%, 70.3% below its 52-week closing high. Volume of 675.2K shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: +6.6% over one month, -55.1% over six months, -50.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $16.07M, up 112.7% from a year earlier, with a net margin of -44.7%.

Short interest was 2.5M shares at the Oct 15 settlement, up 14.1% from the prior report (7.3% of float, 1.2 days to cover).

Market cap$124.7M59.4M shares
Revenue · quarter$16.1M+112.7% YoY
Diluted EPS$-0.10—
P/E · TTM—P/S 3.4×
Net margin-44.7%Gross 100.0%
Dividend yieldNone
52-week range1.85 – 7.07−70.3% from high
Volume675.2K1.01× 20-day avg
Volatility · 60d98.0%Annualised
Short % of float7.3%1.2 days to cover
Net cash$167.6MCash $167.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.4%1M +6.6%3M −62.3%6M −55.1%YTD −61.1%1Y −50.1%3Y −39.8%5Y −83.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum21
Revenue growth85
Net margin46
Value (low P/E)—
Size43

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.5M+14.1% vs prior
Days to cover1.2Settled Oct 15
% of float7.3%
Short vol. 10d30.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FHTXFoghorn Therapeutics$2.10−1.41%−55.1%+112.7%−44.7%—$124.7M
NKTXNkarta$1.73+13.07%−47.9%———$123.9MCompare
YARWYarrow Bioscience$14.91−18.84%————$125.8MCompare
NERVMinerva Neurosciences$2.57+9.36%−58.7%———$122.7MCompare
DERMJourney Medical$4.73+1.94%−9.2%+18.9%−1.7%—$133.5MCompare
SPRBSpruce Biosciences$46.61+8.88%−19.5%———$134.0MCompare
ANIXAnixa Biosciences$3.28+7.37%+7.2%———$114.0MCompare
PYXSPyxis Oncology$1.66+1.22%−27.8%−100.0%——$138.5MCompare
ORGOOrganogenesis Holdings$0.8700+4.19%−66.0%−56.7%−227.0%—$111.9MCompare

News about Foghorn Therapeutics

All news →
Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · Oct 28, 2026▲ PositiveStep Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorGlobeNewswire Inc. · Jul 1, 2026NeutralFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingGlobeNewswire Inc. · Apr 9, 2026▲ Positive

Quick answers

What does Foghorn Therapeutics do?
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets.
What is FHTX's market cap?
$124.71M, based on the Nov 4 close of $2.10.
Does Foghorn Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FHTX is sold short?
2.5M shares, 7.3% of float, as of Oct 15, 2026.
What sector is FHTX in?
Healthcare, in the Pharmaceuticals industry.

About Foghorn Therapeutics

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

HQ: Cambridge, MA106 employeesListed Oct 23, 2020foghorntx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology